½ÃÀ庸°í¼­
»óǰÄÚµå
1572041

¼¼°èÀÇ ¾ÈƼÇǸ° ½ÃÀå : Á¦Ç° À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, À¯Åë ä³Îº°, ¿¬·ÉÃþº°, Ä¡·á Ŭ·¡½ºº° - ¿¹Ãø(2025-2030³â)

Antipyrine Market by Product Type (Capsules, Injectable, Liquid), Application (Anti-Inflammatory, Arthritis, Cold and Flu), End User, Distribution Channel, Age Group, Therapeutic Class - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 186 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¾ÈƼÇǸ° ½ÃÀåÀº 2023³â¿¡ 3¾ï 6,322¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 3¾ï 8,299¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, CAGR 4.34%·Î ¼ºÀåÇÒ Àü¸ÁÀ̰í, 2030³â¿¡´Â 4¾ï 8,929¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

¾ÈƼÇǸ°Àº ÁÖ·Î ÁøÅë ÇØ¿­Á¦·Î »ç¿ëµÇ´Â ÀǾà È­ÇÕ¹°·Î ÀÇ·á ºÐ¾ß¿¡¼­ ´Ù¾çÇÑ ¿ëµµ°¡ ¹ß°ßµÇ°í ÀÖ½À´Ï´Ù. ¾ÈƼÇǸ°ÀÇ Çʿ伺Àº ÅëÁõÀ» ¿ÏÈ­ÇÏ°í ¿­À» ³·Ãß´Â ±× È¿´É¿¡¼­ ¹ß»ýÇϸç, ÀϺΠ½ÃÆÇ¾àÀ̳ª 󹿾àÀÇ Á¦Á¦¿¡ ÇʼöÀûÀÎ ¼ººÐÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÃÖÁ¾ ¿ëµµÀÇ ¹üÀ§´Â ÁÖ·Î ±ÍÀÇ ÅëÁõ°ú ¿°ÁõÀ» ¿ÏÈ­Çϱâ À§ÇÑ Á¡À̾׿¡ ´ëÇÑ Á¦Çü°ú ¾à¹°µ¿ÅÂÇÐÀû Ư¼º¿¡ ÀÇÇÑ Áø´Ü ¿ëµµ¿¡ ´ëÇÑ ÀáÀçÀûÀÎ »ç¿ëÀ» Æ÷ÇÔÇÕ´Ï´Ù. ½ÃÀå ÀλçÀÌÆ®¿¡ µû¸£¸é, ¾ÈƼÇǸ°ÀÇ ¼ºÀåÀº ±Í °¨¿°ÀÇ À¯º´·ü Áõ°¡, È¿°úÀûÀÎ ÅëÁõ °ü¸® ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ ¹ßÀü µîÀÇ ¿äÀο¡ ÀÇÇØ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¾ÈƼÇǸ°ÀÇ ÀáÀçÀûÀÎ °¡´É¼ºÀº º¸´Ù Á¾ÇÕÀûÀÎ ÅëÁõ ¿ÏÈ­ÀÇ ¼±ÅÃÀ» ¿ä±¸ÇÏ´Â ¼ÒºñÀÚÃþÀÇ È®´ë¿¡ ´ëÀÀÇÏ´Â »õ·Î¿î ¾àÁ¦ÀÇ Á¶ÇÕ ¹× Á¦Á¦¿¡¼­ÀÇ ¾ÈƼÇǸ° ¿ªÇÒÀÇ Å½±¸¿¡ ÀÖ½À´Ï´Ù. ¿©±â¿¡´Â ƯÈ÷ Ç¥Àû Ä¡·áÁ¦·Î¼­ ¾ÈƼÇǸ° ±â¹Ý ¾à¹°ÀÇ »ýüÀÌ¿ë·ü°ú È¿´ÉÀ» ³ôÀ̱â À§ÇÑ ³ª³ë±â¼úÀÇ »õ·Î¿î ¿¬±¸ Ȱ¿ëÀÌ Æ÷ÇԵ˴ϴÙ. ±×·¯³ª ½ÃÀåÀº ¾ö°ÝÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ ¿öÅ©, Àå±â°£ »ç¿ë°ú °ü·ÃµÈ ºÎÀÛ¿ë °¡´É¼º, ´ëü ¿ä¹ý°úÀÇ °æÀï°ú °°Àº ¹®Á¦¿¡ Á÷¸éÇØ ÀÖÀ¸¸ç, ÀÌ´Â ¼ºÀåÀ» ¹æÇØÇÏ´Â ¿äÀÎÀÌ µÇ¾ú½À´Ï´Ù. »õ·Î¿î ±âȸ¸¦ Æ÷ÂøÇϱâ À§ÇØ ±â¾÷Àº ¾à¹°Àü´Þ ¹× ¸ÂÃãÇü ÀÇ·áÀÇ Çõ½Å¿¡ ÁÖ·ÂÇÏ°í Æ¯Á¤ Àα¸ ¿ªÇÐÀÇ ¿ä±¸¿¡ ºÎÀÀÇØ¾ß ÇÕ´Ï´Ù. ¿¬±¸±â°ü°ú ¿¬°èÇÏ¿© ±× ¸ÞÄ¿´ÏÁòÀ» »ó¼¼ÇÏ°Ô Á¶»çÇϰí, »õ·Î¿î Ä¡·áÀû ÀûÀÀÁõÀ» ¹ß°ßÇÏ´Â °ÍÀÌ µ¹ÆÄ±¸¸¦ °¡Á®¿Í ½ÃÀå¿¡¼­ÀÇ Á¸Àç°¨À» ³ôÀÔ´Ï´Ù. ¶ÇÇÑ, ÃæºÐÇÑ ¼­ºñ½º¸¦ ¹ÞÁö ¸øÇÑ ½ÃÀå¿¡¼­ Àü·«Àû ÆÄÆ®³Ê½ÊÀ» ¸Î°í Áö¸®Àû ¹üÀ§¸¦ È®´ëÇÏ´Â °ÍÀÌ ¼ºÀåÀ» µÞ¹ÞħÇÒ ¼ö ÀÖ½À´Ï´Ù. ½ÃÀå °æÀïÀº Ä¡¿­ÇÏÁö¸¸ ¹Ì·¡°¡ ÀÖ½À´Ï´Ù. ¾÷°è ±â¾÷Àº ÀûÀÀ·Â°ú ¼±°ß¼ºÀ» À¯ÁöÇϰí ÄÄÇöóÀ̾𽺸¦ º¸ÀåÇÏ¸ç ¾ÈÀü ¹®Á¦¸¦ ÇØ°áÇϸ鼭 Çõ½ÅÀûÀÎ ¿ëµµÀ» ã°í ½ÃÀå °ü·Ã¼º°ú ¸®´õ½ÊÀ» À¯ÁöÇØ¾ß ÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023³â) 3¾ï 6,322¸¸ ´Þ·¯
¿¹»ó³â(2024³â) 3¾ï 8,299¸¸ ´Þ·¯
¿¹Ãø³â(2030³â) 4¾ï 8,929¸¸ ´Þ·¯
CAGR(%) 4.34%

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â ¾ÈƼÇǸ° ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

¾ÈƼÇǸ° ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ðÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÅõÀÚ°áÁ¤, Àü·«Àû °áÁ¤ Á¤¹ÐÈ­, »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ¿¡ ´ëºñÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ» »Ó¸¸ ¾Æ´Ï¶ó, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¶Ç´Â ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Ç׿°Áõ ÀÛ¿ë¿¡ ÁÖ¸ñÇÑ Á¶»ç Ȱµ¿ÀÇ È®´ë
    • ½ÃÀå ¿ªÇп¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¾ÈƼÇǸ°ÀÇ ½ÃÆÇ¾à¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
    • º¸´Ù ÁÁÀº ÀÓ»ó °á°ú¸¦ ¾ò±â À§ÇÑ ¾ÈƼÇǸ°À» ÀÌ¿ëÇÑ º´¿ë ¿ä¹ý °³¹ß¿¡ ÁÖ¸ñ °íÁ¶
    • Á¦³×¸¯ ¾ÈƼÇǸ° °³¹ß¿¡ ´ëÇÑ Á¤ºÎÀÇ ´ëó ¹× ÀÚ±Ý Áö¿øÀÌ ½ÃÀå ¼ºÀå µÞ¹Þħ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¾ÈƼÇǸ°°ú °ü·ÃµÈ ÀáÀçÀûÀÎ ºÎÀÛ¿ë°ú ¾ÈÀü¼º ¿ì·Á¿¡ ´ëÇÑ °¨½Ã ¹× »çȸÀû ÀÎÁö Áõ°¡°¡ ¼ÒºñÀÚÀÇ ½Å·Ú¿Í ¸ÅÃâ¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ½.
    • ¾ÈƼÇǸ°ÀÇ Á¦Á¶¿¡ ÇÊ¿äÇÑ °íǰÁú ¿øÀç·á Á¶´Þ ¹× ¾ÈÁ¤ÀûÀÎ °ø±Þ¿¡ ´ëÇÑ °úÁ¦.
  • ½ÃÀå ±âȸ
    • ÇコÄɾî ÅõÀÚ Áõ°¡¿¡ ÀÇÇÑ ¾ÈƼÇǸ°ÀÇ ÀǾàǰ Á¦Á¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
    • ¹Ý·Áµ¿¹°ÀÇ »çÀ°·ü »ó½Â¿¡ ÀÇÇÑ µ¿¹°¿ë ÀǾàǰ¿¡ ´ëÇÑ ¾ÈƼÇǸ° ¿ëµµ È®´ë
    • °í·ÉÈ­ °æÇâ¿¡ ÀÇÇÑ ÅëÁõ °ü¸® ¼Ö·ç¼Ç¿¡ À־ ¾ÈƼÇǸ°ÀÇ ¿ä±¸ Áõ°¡
  • ½ÃÀåÀÇ °úÁ¦
    • ¾ÈƼÇǸ° ¾÷°è¿¡ À־ °ø±Þ¸Á È¥¶õ°ú ¿øÀç·á °¡°ÝÀÇ º¯µ¿¿¡ ´ëÀÀ
    • ¾ÈƼÇǸ° »ý»ê °øÁ¤¿¡¼­ ÃÖ÷´Ü ±â¼úÀÇ Áøº¸ ¹× Çõ½ÅÀÇ µµÀÔ

Porter's Five Forces : ¾ÈƼÇǸ° ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ¾ÈƼÇǸ° ½ÃÀå °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ޱ¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®¸¦ ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÒ ¼ö ÀÖÀ¸¸ç, º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¾ÈƼÇǸ° ½ÃÀå¿¡¼­ ¿ÜºÎ·ÎºÎÅÍÀÇ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¾ÈƼÇǸ° ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇϴµ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ¾ÈƼÇǸ° ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

¾ÈƼÇǸ° ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õµéÀº °æÀïÀÌ Ä¡¿­ÇØÁö´Â °¡¿îµ¥ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : ¾ÈƼÇǸ° ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¾ÈƼÇǸ° ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ Çà·ÄÀ» ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ : ¾ÈƼÇǸ° ½ÃÀå¿¡¼­ ¼º°øÀ» À§ÇÑ ±æÀ» ±×¸³´Ï´Ù.

¾ÈƼÇǸ° ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ Á¸À縦 °­È­ÇÏ·Á´Â ±â¾÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í °³¼±À» À§ÇØ ³ë·ÂÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, ¿¬±¸°³¹ß Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð ¹× ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ ¹× ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ¾ÈƼÇǸ°ÀÇ Ç׿°Áõ Ư¼º¿¡ ÃÊÁ¡À» ¸ÂÃá Á¶»ç Ȱµ¿ È®´ë
      • ½ÃÆÇ¾à ¼ö¿ä Áõ°¡°¡ ½ÃÀå ¿ªÇп¡ ¿µÇâ
      • º¸´Ù ÁÁÀº ÀÓ»ó °á°ú¸¦ ¾ò±â À§Çؼ­, ¾ÈƼÇǸ°À» Ư¡À¸·Î ÇÏ´Â º´¿ë ¿ä¹ý °³¹ß Áß½Ã
      • Á¦³×¸¯ ÀǾàǰ °³¹ß¿¡ ´ëÇÑ Á¤ºÎÀÇ ´ëó ¹× ÀÚ±Ý Á¦°øÀÌ ½ÃÀå ¼ºÀå µÞ¹Þħ
    • ¾ïÁ¦¿äÀÎ
      • ¾ÈƼÇǸ°°ú °ü·ÃµÈ ÀáÀçÀûÀÎ ºÎÀÛ¿ë°ú ¾ÈÀü ¹®Á¦¿¡ ´ëÇÑ ¸ð´ÏÅ͸µ°ú ÀÏ¹Ý ÀνÄÀÌ ³ô¾ÆÁ® ¼ÒºñÀÚÀÇ ½Å·Ú¿Í ÆÇ¸Å¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.
      • ¾ÈƼÇǸ°ÀÇ Á¦Á¶¿¡ ÇÊ¿äÇÑ °íǰÁú ¿øÀç·áÀÇ Á¶´Þ°ú ¾ÈÁ¤ÀûÀÎ °ø±ÞÀ» È®º¸ÇÏ´Â °ÍÀÌ °úÁ¦ÀÌ¸ç »ý»ê È¿À²¿¡ ¿µÇâÀ» ÁÙ ¼ö ÀÖ½À´Ï´Ù.
    • ±âȸ
      • ÇコÄɾî ÅõÀÚ Áõ°¡¿¡ ÀÇÇØ ÀǾàǰ ó¹æ¿¡ À־ÀÇ ¾ÈƼÇǸ° ¼ö¿ä Áõ°¡
      • ¹Ý·Áµ¿¹°ÀÇ »çÀ°·üÀÇ »ó½Â¿¡ ÀÇÇØ ¼öÀǾ࿡ À־ÀÇ ¾ÈƼÇǸ° ÀÀ¿ë È®´ë
      • Àα¸ÀÇ °í·ÉÈ­ÀÇ µ¿Çâ¿¡ ÀÇÇØ ÅëÁõ °ü¸® ¼Ö·ç¼Ç¿¡ À־ÀÇ ¾ÈƼÇǸ° ¼ö¿ä°¡ Áõ°¡
    • °úÁ¦
      • ¾ÈƼÇǸ° ¾÷°è¿¡¼­°ø±Þ¸ÁÀÇ È¥¶õ°ú ¿øÀç·á °¡°ÝÀÇ º¯µ¿ÀÇ °ü¸®
      • ¾ÈƼÇǸ°ÀÇ »ý»ê °øÁ¤¿¡ ÃÖ÷´Ü ±â¼ú Áøº¸¿Í Çõ½Å µµÀÔ
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTLE ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå ¾ÈÆ¼ÇǸ° ½ÃÀå : Á¦Ç° À¯Çüº°

  • ĸ½¶
  • ÁÖ»ç °¡´É
  • ¾×ü
  • ºÐ¸»
  • ÅÂºí¸´

Á¦7Àå ¾ÈÆ¼ÇǸ° ½ÃÀå : ¿ëµµº°

  • Ç׿°Áõ
  • °üÀý¿°
  • °¨±â¿Í µ¶°¨
  • ÇØ¿­
  • ÅëÁõ ¿ÏÈ­

Á¦8Àå ¾ÈÆ¼ÇǸ° ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • Ŭ¸®´Ð
  • ȨÄɾî
  • º´¿ø
  • ¿¬±¸±â°ü

Á¦9Àå ¾ÈÆ¼ÇǸ° ½ÃÀå : À¯Åë ä³Îº°

  • ¾à±¹
  • º´¿ø ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹
  • ¼Ò¸Å ¾à±¹

Á¦10Àå ¾ÈÆ¼ÇǸ° ½ÃÀå : ¿¬·ÉÃþº°

  • ¼ºÀÎ
  • ³ë³âÀÇÇÐ
  • ¼Ò¾Æ°ú

Á¦11Àå ¾ÈÆ¼ÇǸ° ½ÃÀå : Ä¡·á Ŭ·¡½ºº°

  • ÁøÅëÁ¦
  • ÇØ¿­Á¦
  • NSAIDs

Á¦12Àå ¾Æ¸Þ¸®Ä«ÀÇ ¾ÈƼÇǸ° ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦13Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¾ÈƼÇǸ° ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦14Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¾ÈƼÇǸ° ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦15Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º(2023³â)
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼® ¹× Á¦¾È
AJY 24.10.24

The Antipyrine Market was valued at USD 363.22 million in 2023, expected to reach USD 382.99 million in 2024, and is projected to grow at a CAGR of 4.34%, to USD 489.29 million by 2030.

Antipyrine, a pharmaceutical compound primarily used as an analgesic and antipyretic, has found various applications in the medical field. The necessity for antipyrine arises from its efficacy in alleviating pain and reducing fever, making it an essential component in the formulation of several over-the-counter and prescription medications. The end-use scope primarily includes its incorporation in ear drop solutions to relieve ear pain and inflammation and its potential use in diagnostic applications due to its pharmacokinetic properties. Market insights indicate that the growth of antipyrine is influenced by factors such as increased prevalence of ear infections, rising demand for effective pain management solutions, and advancements in drug delivery systems. A potential opportunity lies in the exploration of antipyrine's role in novel drug combinations and formulations, catering to an expanding consumer base seeking more comprehensive pain relief options. This includes leveraging emerging research in nanotechnology to enhance the bioavailability and efficacy of antipyrine-based medications, particularly for targeted therapies. However, the market faces challenges such as stringent regulatory frameworks, potential side effects associated with prolonged use, and competition from alternative therapies, which can impede growth. To capture emerging opportunities, businesses should focus on innovations in drug delivery and personalized medicine, catering to specific demographic needs. Collaborating with research institutions for in-depth studies on antipyrine's mechanism and discovering new therapeutic indications can lead to breakthroughs, fortifying market presence. Additionally, expanding geographic reach through strategic partnerships in underserved markets could bolster growth. The market is competitive yet promising, urging industry players to remain adaptive and forward-thinking, ensuring compliance and addressing safety concerns while exploring innovative applications to sustain market relevance and leadership.

KEY MARKET STATISTICS
Base Year [2023] USD 363.22 million
Estimated Year [2024] USD 382.99 million
Forecast Year [2030] USD 489.29 million
CAGR (%) 4.34%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antipyrine Market

The Antipyrine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Expansion of research activities focusing on the anti-inflammatory properties of antipyrine
    • Escalating demand for over-the-counter antipyrine medications influencing market dynamics
    • Enhanced focus on developing combination therapies featuring antipyrine for better clinical outcomes
    • Government initiatives and funding for the development of generic antipyrine medications boosting market growth
  • Market Restraints
    • The increasing scrutiny and public awareness of the potential side effects and safety concerns associated with antipyrine, impacting consumer trust and sales
    • The challenges in sourcing and ensuring the consistent supply of high-quality raw materials required for manufacturing antipyrine, which can affect production efficiency
  • Market Opportunities
    • Increased demand for antipyrine in pharmaceutical formulations driven by rising healthcare investments
    • Expansion of antipyrine applications in veterinary medicines due to rising pet adoption rates
    • Growing need for antipyrine in pain management solutions spurred by aging population trends
  • Market Challenges
    • Managing supply chain disruptions and raw material price volatility in the antipyrine industry
    • Implementing cutting-edge technological advancements and innovation in the antipyrine production process

Porter's Five Forces: A Strategic Tool for Navigating the Antipyrine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antipyrine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antipyrine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antipyrine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antipyrine Market

A detailed market share analysis in the Antipyrine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antipyrine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antipyrine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antipyrine Market

A strategic analysis of the Antipyrine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antipyrine Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Hoffmann-La Roche, Johnson & Johnson, Merck & Co., Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Shionogi, Sun Pharmaceutical, Takeda Pharmaceutical Company, and Teva Pharmaceutical Industries.

Market Segmentation & Coverage

This research report categorizes the Antipyrine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Capsules, Injectable, Liquid, Powder, and Tablets.
  • Based on Application, market is studied across Anti-Inflammatory, Arthritis, Cold and Flu, Fever Reduction, and Pain Relief.
  • Based on End User, market is studied across Clinics, Homecare, Hospitals, and Research Institutes.
  • Based on Distribution Channel, market is studied across Drug Stores, Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Age Group, market is studied across Adults, Geriatrics, and Pediatrics.
  • Based on Therapeutic Class, market is studied across Analgesics, Antipyretics, and NSAIDs.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Expansion of research activities focusing on the anti-inflammatory properties of antipyrine
      • 5.1.1.2. Escalating demand for over-the-counter antipyrine medications influencing market dynamics
      • 5.1.1.3. Enhanced focus on developing combination therapies featuring antipyrine for better clinical outcomes
      • 5.1.1.4. Government initiatives and funding for the development of generic antipyrine medications boosting market growth
    • 5.1.2. Restraints
      • 5.1.2.1. The increasing scrutiny and public awareness of the potential side effects and safety concerns associated with antipyrine, impacting consumer trust and sales
      • 5.1.2.2. The challenges in sourcing and ensuring the consistent supply of high-quality raw materials required for manufacturing antipyrine, which can affect production efficiency
    • 5.1.3. Opportunities
      • 5.1.3.1. Increased demand for antipyrine in pharmaceutical formulations driven by rising healthcare investments
      • 5.1.3.2. Expansion of antipyrine applications in veterinary medicines due to rising pet adoption rates
      • 5.1.3.3. Growing need for antipyrine in pain management solutions spurred by aging population trends
    • 5.1.4. Challenges
      • 5.1.4.1. Managing supply chain disruptions and raw material price volatility in the antipyrine industry
      • 5.1.4.2. Implementing cutting-edge technological advancements and innovation in the antipyrine production process
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antipyrine Market, by Product Type

  • 6.1. Introduction
  • 6.2. Capsules
  • 6.3. Injectable
  • 6.4. Liquid
  • 6.5. Powder
  • 6.6. Tablets

7. Antipyrine Market, by Application

  • 7.1. Introduction
  • 7.2. Anti-Inflammatory
  • 7.3. Arthritis
  • 7.4. Cold and Flu
  • 7.5. Fever Reduction
  • 7.6. Pain Relief

8. Antipyrine Market, by End User

  • 8.1. Introduction
  • 8.2. Clinics
  • 8.3. Homecare
  • 8.4. Hospitals
  • 8.5. Research Institutes

9. Antipyrine Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Drug Stores
  • 9.3. Hospital Pharmacies
  • 9.4. Online Pharmacies
  • 9.5. Retail Pharmacies

10. Antipyrine Market, by Age Group

  • 10.1. Introduction
  • 10.2. Adults
  • 10.3. Geriatrics
  • 10.4. Pediatrics

11. Antipyrine Market, by Therapeutic Class

  • 11.1. Introduction
  • 11.2. Analgesics
  • 11.3. Antipyretics
  • 11.4. NSAIDs

12. Americas Antipyrine Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Antipyrine Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Antipyrine Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie
  • 2. Amgen
  • 3. AstraZeneca
  • 4. Bayer
  • 5. Bristol-Myers Squibb
  • 6. Eli Lilly and Company
  • 7. Gilead Sciences
  • 8. GlaxoSmithKline
  • 9. Hoffmann-La Roche
  • 10. Johnson & Johnson
  • 11. Merck & Co.
  • 12. Novartis
  • 13. Novo Nordisk
  • 14. Pfizer
  • 15. Roche
  • 16. Sanofi
  • 17. Shionogi
  • 18. Sun Pharmaceutical
  • 19. Takeda Pharmaceutical Company
  • 20. Teva Pharmaceutical Industries
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦